Last Updated on March 14, 2025 by The Health Master
Warning letter
Dexcom, a prominent medical device company which manufactures glucose monitoring (CGM) systems, has revealed that it received a warning letter from the U.S. Food and Drug Administration (USFDA).
USFDA has conducted inspection at its key manufacturing hubs, i.e., at its two manufacturing facilities in U.S.
Manufacturing and Quality Management
The USFDA has issued a warning letter due to some issues with manufacturing processes and quality management systems at its facilities located in San Diego, California, and Mesa, Arizona.
While Dexcom refrained from disclosing the precise number of observations made across the two sites, the letter clearly points to areas requiring immediate attention.
This warning letter raises some critical questions regarding the production standards followed in the facility of Dexcom, and these standards are very essential for maintaining the standards at par with respect to the efficacy and safety of their CGM devices being manufactured in the facility.
Addressing the Issues by Dexcom
Dexcom’s management has expressed confidence in their ability to address the issues raised by the USFDA through its warning letter.
The company stated that they do not anticipate a “material impact” on their manufacturing capacity or their previously issued sales guidance for the fiscal year 2025.
Dexcom has already taken significant steps to resolve the issues or observations raised in “Form 483,” and the company is in the process of replying to these issues in the form of a written response.
A Form 483, in essence, is a report detailing objectionable conditions observed by USFDA inspectors during their facility inspections.
Navigating Regulatory Compliance
Dexcom’s manufacturing operations are spread across three primary locations:
Its headquarters in San Diego,
- California; a facility in Mesa,
- Arizona; and another in Penang, Malaysia.
According to recent regulatory filings, the company operates approximately 80,600 square feet of laboratory space and 159,600 square feet of controlled environment rooms across these three sites.
Maintaining stringent quality control across such a diverse manufacturing footprint is paramount.
The USFDA’s warning letter underscores the importance of consistent adherence to regulatory standards, regardless of location.
What is a Form 483?
A Form 483 is an USFDA report that lists objectionable conditions observed by USFDA inspectors during facility inspections.
Q. What are the potential consequences of an USFDA warning letter?
A. Consequences can range from mandated corrective actions to potential fines or even facility closures in severe cases.
Q. Will the warning letter affect the availability of Dexcom CGM devices?
A. Dexcom has stated they do not expect a material impact on their manufacturing capacity or sales guidance.
Q. What are the main manufacturing locations for Dexcom?
A. Dexcom manufactures its products at its headquarters in San Diego, California, and at its manufacturing facilities in Mesa, Arizona and Penang, Malaysia.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
USFDA issues warning letter to Jagsonpal Pharmaceuticals
Warning letter by USFDA: Let’s know all about it
USFDA issues warning letter to Sanofi
USFDA issues warning letter to Indoco Remedies for Goa facility
USFDA issues warning letters to two Chinese firms over data integrity concerns
USFDA issues warning letter to Zydus for injectables unit at Jarod
DCA Telangana cracks down on distributors for Storage Violations
USFDA issued Form 483 to Alembic Pharma with 1 observation
NPPA fixed retail price of 53 formulations: March 2025
DCC agrees with proposal to amend Rule 89 for better clarity
Gujarat Drug Inspectors Armed with Spectrophotometers for Instant Drug Tests
FDA Punjab to track manufacture and sale of these 7 drugs
OTC Medicines list coming this month: India
Drug recall: Glenmark recalls 15 lakh bottles of this Drug
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
